Introduction
============

Huntington's disease (HD) is a devastating neurodegenerative disease characterized by symptoms of cognitive disorder, motor impairment and mental disturbance. The prevalence of HD is 4--10 per 100, 000 in the western population, and the mean age of onset is 40 years old ([@B86]). It is an autosomal dominant monogenic disease caused by CAG trinucleotide repeats expansion in the *HTT* gene, which translates into huntingtin (HTT) protein with an expanded polyglutamine (polyQ) tract that is prone to misfolding. Although the pathogenic mutant huntingtin (mHTT) is ubiquitously expressed in different types of neural cells in the brain ([@B53]), it causes a preferential loss of medium spiny neurons (MSNs) in the striatum ([@B36]), and the atrophy of caudate and putamen could be clinically imaged by magnetic resonance imaging (MRI) prior to motor symptom onset ([@B1]).

Neuroinflammation, characterized by remarkable gliosis and inflammatory reactions in the central nervous system (CNS), has been described as a prominent sign in various neurodegenerative diseases such as Alzheimer's disease (AD) ([@B106]), Parkinson's disease (PD) ([@B59]), and Amyotrophic Lateral Sclerosis (ALS) ([@B80]). HD is no exception, as mounting evidence indicates that microglia activation could be detected in the brains from pre-symptomatic HD carriers to post-mortem HD patients. Specifically, elevated inflammatory cytokines could be detected in both the CNS and plasma from HD patients ([@B99],[@B100]; [@B5]; [@B94]; [@B81]).

Microglia, the resident macrophage of the CNS, monitor the microenvironment in the CNS and respond to neural damage or degeneration by switching to different activation states ([@B43]). Moreover, CX3CL1-CX3CR1 and CD200-CD200R are two major signaling pathways that function to mediate neuron-microglia interaction and facilitate immunomodulatory and phagocytic activities of microglia in response to degenerated neurons in the CNS ([@B35]). Under normal conditions, resting microglia typically display small cell bodies with fine processes and work as the first line of defense in the CNS ([@B43]). In the presence of adverse stimuli, microglia retract the processes and exhibit swollen shapes ([@B71]). Microglia exhibiting large amoeboid-like cell bodies with no processes or with short stout extensions were seen in both HD patient brain ([@B88]) and YAC128 HD mouse model ([@B27]). In addition, the abnormal morphology of microglia is exacerbated in an age-dependent manner, throughout the course of HD progression. Here, we review the immune-regulatory role of microglia in HD pathology, and discuss potential cellular mechanisms of microglia activation underlying HD pathogenesis.

Pathogenic mHTT and Experimental Models for HD
==============================================

Expanded polyQ tract at the N-terminus of HTT is responsible for protein misfolding and the subsequent aberrant accumulation and aggregates formation. Aggregated mHTT could be detected as inclusion bodies either in the cytoplasm or nuclei ([@B22]; [@B42]). The relative contribution of soluble and aggregated forms of mHTT to the pathogenesis in HD is still unclear. Nevertheless, it is commonly believed that the expression of N-terminal mHTT fragments could lead to HD pathogenesis, and the sizes of the fragments correlate inversely with neurotoxicity ([@B65]; [@B11]).

To facilitate investigation of HD, a variety of HD experimental models with the expression of either full-length or N-terminal fragments of mHTT were generated and studied, such as transgenic animal models ([@B11]), human embryonic stem cell derived models ([@B63]) and HD patients derived induced pluripotent stem cells ([@B111]). Among them, mouse model is one of the most commonly used, due to its relative ease of genetic manipulation and physiological resemblance to human. In **Table [1](#T1){ref-type="table"}**, we provide a summary of most commonly studied HD mouse models, in terms of their genetic background and mHTT expression pattern and level.

###### 

Mouse models of Huntington's disease.

  Mouse       Types                       Poly-Q       Protein                       Protein       Protein expression   
  ----------- ------------ -------------- ------------ ----------------------------- ------------- -------------------- ----------------
  R6/2        Transgenic   Human HTT      150 CAG      Human N-terminal 1--82 a.a.   75%           All                  [@B65]
  N171-82Q    Transgenic   Murine prion   82 CAG       Human N-terminal 1-171 a.a.   20%           Neurons              [@B90]
  Hdh^Q111^   Knock-in     Murine Hdh     111 CAG      Murine full-length Hdh        50% or 100%   All                  [@B110]
  Q140        Knock-in     Murine Hdh     140 CAG      Murine full-length Hdh        50% or 100%   All                  [@B69]
  HdhQ150     Knock-in     Murine Hdh     150 CAG      Murine full-length Hdh        100%          All                  [@B44]
  zQ175       Knock-in     Murine Hdh     175 CAG      Murine full-length Hdh        100%          All                  [@B68]; [@B96]
  YAC128      Transgenic   Human *HTT*    128 CAG      Human full-length mHTT        75%           All                  [@B47]
  BACHD       Transgenic   Human *HTT*    97 CAA/CAG   Human full-length mHTT        150%          All                  [@B37]

Although mHTT is ubiquitously expressed, HD elicits selective cortical and striatal neurodegeneration. To understand mechanisms underlying the preferential neuronal vulnerability, mouse models that express mHTT in selective cell populations were generated using the Cre-Loxp system. For instance, transgenic mice carrying Cre recombinase with different promoters, such as Emx1 or Rgs9, were crossed with BACHD mice, allowing restricted expression of mHTT in the cortex and striatum, respectively ([@B109]). Similarly, mice that express exon1 of mHTT in neurons or only in cortical pyramidal neurons were created by crossing RosaHD mice with Nestin-Cre mice or Emx1-Cre mice ([@B38]). In addition, there are transgenic mice that selectively express mHTT in astrocytes ([@B8]) or oligodendrocytes ([@B51]), which demonstrate the mHTT expression in non-neuronal cells also contributes to the pathogenesis of HD. Mice that express mHTT specifically in microglia have been generated by crossing RosaHD with Cx3cr1-Cre miceD ([@B16]).

Microglial Activation in HD
===========================

Marked astrogliosis and microgliosis were observed in the post-mortem brains of HD patients but not in normal control brains ([@B95]). It was reported that microglia accumulated in all grades of HD patients' brains, and the density correlated to the degree of neuronal loss ([@B88]). Indeed, *in vivo* positron emission tomography (PET) studies revealed that microglial activation was significant in affected HD brain regions and this pathology was more pronounced in more severe cases of HD ([@B78]; [@B82]). Furthermore, PET also detected microglial activation in HD patients prior to disease manifestations ([@B100]). These studies provide strong evidence indicating that microglial activation is an integral part of HD pathogenesis. Nonetheless, whether the activated microglia plays a protective or detrimental role in HD pathogenesis remains to be illustrated.

Reactive Microglial Activation
------------------------------

Although mHTT is widely expressed, MSNs in the striatum are the most susceptible cell type to mHTT-mediated neurotoxicity. Furthermore, mHTT is more abundantly accumulated in neuronal dendrites and nerve terminals than in soma and other cell types, and *in vitro* studies showed that mHTT preferentially formed aggregates along neuronal processes and axonal terminals ([@B60]; [@B114]). Microglia, as an active sensor in the CNS, transform to activated states in response to pathological changes in the CNS ([@B43]). In cortico-striatal brain slice and primary neuronal culture models, neuronal expression of mHTT initiates a local response of microglia, resulting in elevated numbers and activated morphological phenotypes. In particular, these proliferative microglia were prone to position along irregular neurites, but did not directly contributed to neuronal degeneration ([@B56]). Over-activated microglia were demonstrated to be neurotoxic, due to their capacity to release toxins. Therefore, decreased number of reactive microglia coupled with downregulation of inflammatory cytokines was viewed as an indicator of pathologic alleviation in HD ([@B109]; [@B74]), and therapeutic methods aimed at lowering neuronal mHTT expression led to drastic amelioration of concomitant microglia activation ([@B109]). On the other hand, adding exogenous primary microglia to mHTT-expressing neurons increased neuronal survival, and this effect was proportional to the amount of microglia added ([@B56]). Moreover, a recent *in vivo* study showed supplementing normal human glia to transgenic R6/2 HD mice exhibited neuronal protection as well as phenotypic improvement ([@B3]). The above evidence indicates that normal microglia can rescue mHTT-expressing neurons. Nonetheless, whether mHTT expression in microglia results in its phagocytic or immunoregulatory dysfunction, and how this contributes to HD neuropathology remain to be investigated.

Cell-Autonomous Microglial Activation
-------------------------------------

Although mHTT is ubiquitously expressed in all types of cells, the frequency of inclusion bodies was observed at a much lower rate in microglia compared to others ([@B53]), probably owing to the increased immunoproteasome subunits ([@B76]) and autophagosomes ([@B97]), which renders microglia a higher capacity to degrade mHTT. In spite of less mHTT aggregates formed in microglia, a cell autonomous effect induced by intrinsic mutant protein may be responsible for microglia activation and contribute to the pathology in HD as well. It was demonstrated that mHTT expression altered the function of immune cells both centrally and peripherally, and isolated microglia from R6/2 mice were described to be much more hyperactive than wild type microglia in response to stimulation ([@B5]). Intriguingly, using genome-wide approaches, expression of mHTT in microglia was found to promote cell-autonomous pro-inflammatory gene expression in the absence of sterile inflammation and is dependent on the expression and transcriptional activities of the myeloid lineage-determining factors PU.1 and C/EBPs. In addition, mHTT-expressing microglia-mediated cell-autonomous activation exhibits enhanced toxic effects on wild type neurons in comparison to wild type microglia *ex vivo* and after sterile inflammation *in vivo* ([@B16]). However, whether restricting the expression of mHTT in microglia is sufficient to exert neuropathological and behavioral deficits *in vivo* still needs to be investigated.

Interplay between Microglial Activation and Astrocytic Activation
-----------------------------------------------------------------

Previous work suggests over-activation of *N*-methyl-[D]{.smallcaps}-aspartate receptor (NMDAR) by extracellular glutamate is involved in the degeneration of medium-sized spiny neurons in HD ([@B113]). Astrocytes, the major type of glia in brain, express glutamate transporters that uptake extracellular glutamate while mHTT expression in astrocytes diminished this protection against glutamate neurotoxicity ([@B93]). Moreover, selective mHTT expression in astrocytes caused age-dependent neurological symptoms and exacerbated neuronal loss *in vivo* ([@B8], [@B9]). Markedly, reactive astrocytes are accumulated in proximity to degenerated neurons in HD brain, characterized by increased proliferation, cell hypertrophy and the induction of astroglial markers \[e.g., glial fibrillary acidic protein (GFAP)\]. Furthermore, activated astrocytes instead of microglia were shown to upregulate the pro-inflammation in N171-82 HD mice that express mHTT only in neurons, but not in glial cells ([@B48]). However, a recent study revealed that neurotoxic reactive astrocytes could be induced by activated microglia and consequently resulted in a similar expression profile of pro-inflammatory cytokines, which led to a more rapid death of neurons and oligodendrocytes ([@B62]). Herein, the relative contribution by activated astrocytes and activated microglia to neuroinflammation and the eventual HD pathogenesis remains to be elucidated.

Implication of Functional Phenotypes of Microglia in HD
=======================================================

In response to neurodegeneration and the accumulation of misfolded proteins, microglia multiply and adopt a process referred to as priming. Priming makes the microglia susceptible to a secondary inflammatory stimulus, which then triggers an exaggerated inflammatory response ([@B79]). As the main dynamic component of neuroinflammation in the CNS, activated microglia exist along a continuum of two functional states of polarization in which they are able to either expand the damage to neighboring cells, or clear the cell debris followed by tissue repair ([@B54]). In reference to peripheral macrophage polarization, microglia share comparative properties in reaction to acute or prolonged stimuli, and are classified into two extreme phenotypes: the classically activated M1 phenotype and the alternatively activated M2 phenotype. Differences between these two phenotypes range from morphological changes to alteration of representative cytokines, determined by protein or gene expression profiling ([@B25]; [@B50]). To modify this simplified nomenclature, there are other proposals of classifying macrophages into more informative populations ([@B73]) or refining M2 categorization further into alternative activation (M2a), type II alternative activation (M2b) and acquired deactivation (M2c) ([@B107]). Yet the existence of these refined cell populations has not been fully examined in HD brain.

M1 Phenotype of Microglia and Implicated Biomarkers in HD
---------------------------------------------------------

When triggered by extracellular or intracellular stimuli, resident microglia conferred classically activated state named M1 phenotype to initiate and augment the innate immune function in the CNS. Classically activated M1 microglia release pro-inflammatory biomarkers such as redox molecules (NO, iNOS), cytokines (IL-1β, IL-6, IL-8, and TNF-α et al.), chemokines (CCL2, CCL20, and CXCL-1 et al.) and surface receptors (CD16, CD32, CD36, CD68, and CD86 et al.) which can be used to identify M1 phenotype of microglia ([@B28]; [@B75]). *In vitro* and *in vivo* studies declared that M1 microglia could be induced by the treatment of LPS alone, or combining LPS/IFN-γ followed by increased levels of pro-inflammatory cytokines ([@B25]; [@B57]; [@B18]; [@B108]). M1 microglia relevant biomarkers were widely detected in HD brain, which indicates that M1 microglia may play a crucial role in the pathogenesis of HD. Primary glia cells including microglia, isolated from R6/2 transgenic mouse model, showed that iNOS, IL-1β, IL-6, and TNF-α were significantly elevated after LPS treatment ([@B49]), and IL-6 was increased in the microglia of R6/2 mouse brain ([@B5]). In addition, higher levels of IL-1β and IL-8 were secreted by microglia in HD transgenic porcine model ([@B105]). Furthermore, pro-inflammatory cytokines IL-1β, IL-6, IL-8, and TNF-α were elevated both centrally (in the striatum and cerebrospinal fluid) and peripherally (in the plasma) in HD patients ([@B5]; [@B11]; [@B85]). M1 related markers involved in HD were summarized as **Table [2](#T2){ref-type="table"}**.

###### 

Implications of M1 and M2 microglia relevant markers in HD.

  -------------------------------------------------------------------------------------------------------------------------
  M1 marker   Description                 Reference
  ----------- --------------------------- ---------------------------------------------------------------------------------
  IL-1 β      Pro-inflammatory cytokine   Primary microglia isolated from transgenic HD porcine model ([@B105])\
                                          Plasma of HD patient ([@B81])

  IL-6                                    Primary glial cells isolated from R6/2; Plasma and CSF from HD patient ([@B5])\
                                          Plasma of HD patient ([@B19]; [@B81])\
                                          Post-mortem brain of HD patient ([@B94])\
                                          Plasma of HD patient and mouse model ([@B11])

  IL-8                                    Primary microglia isolated from transgenic HD porcine model ([@B105])\
                                          Primary glial cells isolated from R6/2; Plasma and CSF from HD patient ([@B5])\
                                          Plasma of HD patient ([@B81])\
                                          Post-mortem brain of HD patient ([@B94])

  TNF-α                                   Primary glial cells isolated from R6/2; Plasma and CSF from HD patient ([@B5])\
                                          Plasma of HD patient ([@B81])

  CCL2        Chemokine                   Post-mortem brain of HD patient ([@B94])

  MMP-9       Extracellular proteins      Post-mortem brain of HD patient ([@B94])\
                                          Plasma of HD patient and mouse model ([@B11])

  M2 Marker   Description                 Reference

  IL-10       Cytokine                    Post-mortem brain of HD patient ([@B94])

  VEGF        Growth factor               Plasma of HD patient and mouse model ([@B11])

  TGF-β                                   ([@B20])\
                                          Plasma of HD patient and mouse model ([@B11])

  IGF-1                                   Primary microglia isolated from transgenic HD porcine model ([@B104])
  -------------------------------------------------------------------------------------------------------------------------

IL, interleukin; TNF-α, tumor necrosis factor alpha; chemokine CCL2, C-C motif ligand 2; MMP-9, matrix metallopeptidase 9; VEGF, vascular endothelial growth factor; TGF-β, transforming growth factor beta; IGF-1, insulin-like growth factor 1.

M2 Phenotype of Microglia and Implicated Markers in HD
------------------------------------------------------

In contrast to M1 microglia, alternative activated M2 microglia enable phagocytosis and initiate tissue repair and neural regeneration in the CNS ([@B70]). M2 microglia are characterized by producing anti-inflammatory cytokines and growth factors such as IL-10, TGF-β, CD206, Arg1, Ym1 (Chi3l3 in human) and Fizz1 ([@B28]; [@B75]). Of these molecules, IL-10 played a key role in phagocytic microglia to engulf apoptotic cells ([@B12]; [@B15]). CD206, Arg1, and Ym1 were considered as typical markers for the identification of M2 microglia ([@B12]; [@B70]; [@B112]). To recapitulate the phenotype of M2 microglia, manipulation of IL-10 alone or combining IL-4/IL-13 was performed to establish the experimental models ([@B83]; [@B12]; [@B70]). Much less M2 markers were found in HD, as only VEGF and TGF-β were reported to coexist with M1 markers in the plasma and post-mortem brain tissues of HD patients ([@B20]; [@B10]). M2 related markers in HD were summarized as **Table [2](#T2){ref-type="table"}**.

Concurrence and Transformation of M1 and M2 Microglia
-----------------------------------------------------

As illustrated above, M1 and M2 microglia are defined by their contradictory functions and distinctive biomarkers. However, in traumatic brain injury (TBI), up-regulated expression of both M1 and M2 microglia associated genes can be found simultaneously. And co-localization of representative biomarkers of both activation states in the same microglia indicated concurrence of M1 and M2 phenotype following TBI ([@B72]). Consistent phenomenon of concurrent M1/M2 response was found in ALS ([@B14]) and spinal cord injury (SCI) ([@B92]) as well. In addition, M1 microglia are able to transform to M2 microglia, as cyclic adenosine monophosphate (cAMP) has been reported to play a key role in converting LPS/IFN-γ induced M1 microglia to M2 microglia, which augments the anti-inflammatory effects in the presence of IL-4 with increased levels of Arg1 ([@B30]). In addition, switching M1 microglia to M2 microglia was demonstrated to be protective by initiating remyelination in multiple sclerosis (MS) ([@B70]). Concurrent inflammatory profiles of M1 and M2 microglia related biomarkers were also indicated in HD as shown as **Table [2](#T2){ref-type="table"}**.

Signaling Pathways Underlying the Microglial Activation in HD
=============================================================

Transcriptional Factor Nuclear Factor Kappa B (NF-[K]{.smallcaps}B) Pathway
---------------------------------------------------------------------------

Microglia express toll like receptors (TLRs) to recognize extracellular stimuli. TLR-2 is the most expressed TLR in microglia, which is responsible for IL-6 and IL-10 secretion. TLR-3 and TLR-4 are two receptors, which most potently stimulate proinflammatory cytokines secretion, such as IL-12, TNF-α, IL-6, CXCL-10, and IL-10 ([@B52]). Studies showed that TLR-2, TLR-3, and TLR-4 activate microglia and astrocytes in a sequential manner, coupled with elevated IL-1β level ([@B26]). Experimental M1 microglia, obtained by the treatment of LPS or LPS/IFN-γ, were capable to increase TLR-2 and TLR-4 gene expression ([@B66]). Classical TLR signaling involves the intracellular adaptor protein myeloid differentiated 88 (MyD88) to trigger downstream NF-κB signaling cascade and thus upregulates the production of proinflammatory cytokines ([@B101]). NF-κB is sequestered in the cytoplasm by I-κBs, a group of inhibitory proteins ([@B32]). When I-κBs are phosphorylated by I-κB kinase, NF-κB is dissociated from I-κBs and translocated to the nucleus (IKK including subunits of IKKα, IKKβ, and IKKγ) ([@B31]). Consequently, NF-κB regulates downstream inflammatory cytokines gene expression. Soluble mHTT was shown to activate IKK, which in turn upregulates the NF-κB signaling pathway ([@B55]). Trager et al. used proximity ligation assays and offered evidence that mHTT interacted with IKK, which also mediated transcriptional changes of NF-κB signaling with increased levels of IL-1β, IL-6, IL-8, and TNFα. Furthermore, lowering mHTT level by siRNA was shown to ameliorate NF-κB transcriptional dysregulation, and downregulate the expression of pro-inflammatory cytokines in HD ([@B103]).

Kynurenine Pathway (KP)
-----------------------

In mammalian cells, Kynurenine pathway (KP) mediates degradation of the majority of cellular tryptophan through different enzyme branches ([@B29]). The 3-hydroxyanthranilate 3, 4-dioxygenase (KMO) enzyme, which is predominantly expressed in microglia, metabolizes tryptophan to neuroactive 3-hydroxykynurenine (3HK) and quinolinic acid (QUIN) ([@B46]). QUIN could lead to neurotoxicity by acting as a selective agonist on NMDA receptors ([@B98]), and it has been associated with neuroinflammation in various neurological diseases ([@B64]). Through a genome wide screening in yeast, *BNA1*, which encodes the enzyme Bna1 \[3, 4-dioxygenase (KMO)\] involved in the kynurenine pathway, was found to mediate mHTT toxicity by producing high levels of QUIN and 3HK ([@B33]), which activate NMDA receptors and generate toxic free radical, respectively ([@B91]). However, the first and rate-limiting enzyme of the kynurenine pathway, indoleamine 2,3-dioxygenase (IDO), preferentially localizes in microglia ([@B45]), but not in astrocytes or neurons of human brain ([@B41]). A recent study using transgenic N171-82Q HD mouse model revealed that IDO activity was significantly elevated in HD mice compared to wild type control mice ([@B24]). Moreover, previous studies ([@B40], [@B39]) revealed that IDO activity was elevated in the early stage of HD, which contributed to increased levels of HK and QUIN- and NMD-mediated neurotoxicity. Taking into account of the studies above, drugs that can inhibit KP enzymes may offer potential therapeutic approaches by preventing neurotoxicity caused by downstream toxic products ([@B91]). As KMO and QUIN production showed cell type specific expression in microglia, chronic administration of KMO inhibitor JM6 was shown to prevent synaptic degeneration and increase the survival of R6/2 HD mouse model, which is associated with amelioration of microglial activation ([@B115]). In addition, suppressing the expression of tryptophan-2, 3-dioxygenase (TDO), another rate limiting enzyme in KP, was demonstrated to be neuroprotective in MS ([@B58]). Additionally, inhibiting KP is likely to be protective in several neurologic diseases ([@B29]), probably by modulating microglial activation mediated neurotoxicity.

Cannabinoid (CB) Receptors Signaling
------------------------------------

Cannabinoid receptors are a group of G-protein coupled receptors including cannabinoid type 1 (CB~1~) receptors and cannabinoid type 2 (CB~2~) receptors ([@B34]). In particular, CB~2~ receptors were involved in regulating cell proliferation, differentiation and survival through several signaling pathways, which include adenylyl cyclase and cyclic AMP-protein kinase A (PKA), extracellular signal-regulated kinase 1 (ERK1) and ERK2, p38 mitogen-activated protein kinase and JUN N-terminal kinases (JNKs) ([@B4]). In R6/2 HD mouse model, CB~1~ receptors were abundantly expressed in striatal MSNs ([@B13]) and exerted a neuroprotective role through induction of brain-derived neurotrophic factor (BDNF) expression ([@B6]). CB~2~ receptors were reported to be mainly expressed in periphery immune cells, and were barely detected in brain tissue ([@B89]). However, a significant increase of CB~2~ receptors expression was seen in traumatic mouse brain ([@B23]) and in activated microglia in AD mouse model ([@B2]). In addition, activation of CB~2~ receptors in microglia was shown to influence the acquisition of M2 polarization, and this effect was dampened by knocking out CB~2~ receptors ([@B67]). As for HD, a study showed genetic ablation of CB~2~ receptors in R6/2 mouse model exacerbated the behavioral abnormalities and reduced life span, along with accelerated microglial activation ([@B77]). The further impairment in motor activities caused by loss of CB~2~ receptors was recapitulated in BACHD mouse model as well ([@B7]). Therefore, therapeutic approaches targeting CB~2~ receptors in microglia might be promising in treating HD. Indeed, R6/2 mice have been treated with cannabigerol (CBG), a non-psychotropic phytocannabinoid that exerted neuroprotective effects through both CB~1~/CB~2~ receptors-dependent and -independent mechanisms. Administration of CBG significantly improved motor impairment and increased the expression of BDNF and insulin-like growth factor-1 (IGF-1) in treated R6/2 mouse model ([@B104]). In addition, VCE-003, a CBG quinone derivative, also attenuated striatal neuron loss, motor impairment and microglial activation in quinolinic acid (QA) and 3-NP induced HD mouse models ([@B21]). A CB~2~ receptor specific agonist, SR144528, has also been used for treating mice, which reduced the generation of proinflammatory molecules such as TNF-α ([@B87]).

Conclusion and Future Directions
================================

Microglial activation has been found for over a decade in HD brain and indicated as a strong component of neuroinflammation in HD pathogenesis ([@B17]). Microglial activation in HD was reported to be triggered by neuronal mHTT-mediated excitotoxicity or mHTT expression in microglia, however, whether microglial activation makes a significant contribution to HD pathology has not been fully investigated. Polarized M1 phenotype and M2 phenotype of microglia, which have been illustrated in neurological diseases, especially traumatic brain injury ([@B72]) or SCI ([@B57]), exert coherent morphologic and functional features with alteration of central or peripheral inflammatory profiles. Although M1 and M2 microglia relevant biomarkers are found in HD, the definition and identification of these polarized phenotypes of microglia in HD remain to be elucidated. It is possible that microglial activation play dual roles in HD, either detrimental or beneficial, and thus targeting signaling pathways specific in protective properties of microglia may offer potential therapeutics.
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